FDA Clears Medtronic MiniMed Go Smart MDI System

Reuters01-12
FDA Clears Medtronic MiniMed Go Smart MDI System

Medtronic plc has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its MiniMed Go™ Smart Multiple Daily Injection (MDI) system. The system integrates the InPen™ smart insulin pen with the Instinct sensor made by Abbott, all connected through the MiniMed Go™ app. The MiniMed Go™ system is cleared for individuals with insulin-requiring type 1 and type 2 diabetes aged 7 years and older, as well as for children ages 2 to 6 years under the supervision of an adult caregiver. The commercial launch of the MiniMed Go™ system is expected to begin in the U.S. this spring. Compatibility of the Simplera™ sensor with MiniMed Go™ is currently under FDA review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief via PR Newswire (Ref. ID: CG60970) on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment